MERS + SARS-COV-2 Combo Event
MERS Situation Update - January 2020
https://t.co/K2AB0fTpJT
SA Cases:
https://t.co/ix083ozN0v
UAE Cases:
https://t.co/eCBVg3oSPo
The PEPTIDES again!
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) October 21, 2020
"Such a peptide commonality is unexpected and highly improbable from a mathematical point of view"
Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccinehttps://t.co/yLQoUtxtv2
via @gerdosi https://t.co/lsCv2j4gf9 pic.twitter.com/hdgM5KZd39
1. From Day 1, SARS-COV-2 was very well adapted to humans .....and transgenic hACE2 Mice https://t.co/TNE4tuLkqN
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) February 18, 2021
2. High Probability of serial passaging in Transgenic Mice expressing hACE2 in genesis of SARS-COV-2 https://t.co/B3eR764c1Z
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) February 18, 2021
1. Reversion of molecularly engineered, partially attenuated, very virulent infectious bursal disease virus during infection of commercial chickenshttps://t.co/wOg1Ekl3Xp
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) February 24, 2021
2. Reversion to Virulence of Attenuated Canine Distemper Virus In Vivo and In Vitrohttps://t.co/xhjOEYEWTY
3. pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replicationhttps://t.co/jHmujgDVAC
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) February 24, 2021
"we don't negotiate salaries" really means "we'd prefer to negotiate massive signing bonuses and equity grants, but we'll negotiate salary if you REALLY insist" https://t.co/80k7nWAMoK
— Aditya Mukerjee, the Otterrific \U0001f3f3\ufe0f\u200d\U0001f308 (@chimeracoder) December 4, 2018